Advertisement
Singapore markets closed
  • Straits Times Index

    3,293.13
    +20.41 (+0.62%)
     
  • S&P 500

    5,082.74
    +12.19 (+0.24%)
     
  • Dow

    38,508.41
    +4.72 (+0.01%)
     
  • Nasdaq

    15,799.92
    +103.28 (+0.66%)
     
  • Bitcoin USD

    66,120.52
    -545.70 (-0.82%)
     
  • CMC Crypto 200

    1,427.21
    +3.11 (+0.22%)
     
  • FTSE 100

    8,059.33
    +14.52 (+0.18%)
     
  • Gold

    2,333.70
    -8.40 (-0.36%)
     
  • Crude Oil

    82.88
    -0.48 (-0.58%)
     
  • 10-Yr Bond

    4.6480
    +0.0500 (+1.09%)
     
  • Nikkei

    38,460.08
    +907.92 (+2.42%)
     
  • Hang Seng

    17,201.27
    +372.34 (+2.21%)
     
  • FTSE Bursa Malaysia

    1,571.48
    +9.84 (+0.63%)
     
  • Jakarta Composite Index

    7,174.53
    +63.72 (+0.90%)
     
  • PSE Index

    6,572.75
    +65.95 (+1.01%)
     

The FDA Just Approved an RSV Vaccine -- and It Isn't From Moderna or Pfizer

The FDA Just Approved an RSV Vaccine -- and It Isn't From Moderna or Pfizer

Moderna (NASDAQ: MRNA) and Pfizer (NYSE: PFE) are two healthcare companies aiming to produce a vaccine for the respiratory syncytial virus (RSV). In trials, their vaccine candidates have been proving highly effective, and it may not be long before these COVID-19 vaccine makers are fighting for market share again -- this time in the RSV market. The Food and Drug Administration (FDA) recently approved an RSV vaccine, and it wasn't from either of these two companies.